Optimind Pharma – Debenture Conversion
TORONTO, ON / ACCESSWIRE / January 26, 2024 / Optimind Pharma Corp. (CSE:OMND) (the “Optimind” or the “Company”) advises that it has reached agreement with holders of principal amount $303,750 convertible debentures maturing on January 28, 2024 (the “Debentures”) to convert the principal and interest at a price of $0.025 per share. The total principal amount of Debentures outstanding is $507,250, and the conversion price of $0.025 is available to all holders of the Debentures.
The original conversion price of the Debentures was $0.20 per unit, but the conversion terms have been amended to take into account the current trading price of the Company’s shares.
If all the Debentures and accrued interest is converted, a total of 23,333,500 shares will be issued.
About Optimind Pharma
Optimind Pharma is an emerging provider of psychedelic therapies. From specializing in prescribing medical cannabis, ketamine-assisted treatment, and other psychedelic-enhanced psychotherapy modalities, Optimind Pharma helps individuals suffering from PTSD, anxiety, depression, and other mental illnesses and disabilities.
Optimind exists to combine the power of psychedelic medicine with the science of psychology to provide legal psychedelic enhanced psychotherapy in a safe, controlled environment.
To learn more about Optimind Pharma, visit https://optimindpharma.com/.
Forward-Looking Information
This news release contains forward-looking information within the meaning of Canadian securities legislation concerning the business of the Company. Forward-looking information is based on certain key expectations and assumptions made by the management of the Company. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Forward looking information in this news release includes statements regarding, but not limited to: Optimind’s goal to become a leader in alternative, plant-based treatments and remedies for physical, mental health and optimal functioning; and the belief that the new license positions Optimind for continued growth as it expands the Company’s capabilities and revenue streams. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include: the availability of a qualified workforce; changes in regulations or licensing affecting the Company’s business; patients’ access to products containing controlled substances and other factors beyond the control of the Company. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Media Contact:
Corey Matthews
info@optimindpharma.ca
SOURCE: Optimind Pharma
View the original press release on accesswire.com
